Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Growth differentiation factor 15 is not associated with glycemic control in patients with type 2 diabetes mellitus treated with metformin: a post-hoc analysis of AIM study

Fig. 1

A The comparison of serum GDF15 levels between baseline and endpoint of ACA group and MET group; B-F The comparison of ΔGDF15, ΔBMI, ΔFPG, Δ2-h PG and ΔHbA1c levels between M1 and M2 subgroup (divided by the median of ΔGDF15 in MET group; M1, ΔGDF15 ≤ 338.50 pg/mL; M2, ΔGDF15 > 338.50 pg/mL). GDF15, growth differentiation factor 15; BMI, body mass index; FPG, fasting plasma glucose; 2-h PG, 2-h postprandial plasma glucose; HbA1c, glycated hemoglobin A1c

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us